Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.

@article{Moreno2013RandomizedCO,
  title={Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.},
  author={Ra{\'u}l Moreno and Eul{\'o}gio Garcia and Rui Campante Teles and Jos{\'e}-Ram{\'o}n Rumoroso and Henrique Cyrne Carvalho and Francisco Javier Goicolea and Jos{\'e} Moreu and Josefa Mauri and Manel Sabat{\'e} and Vicente Mainar and L. C. Patricio and Mariano Vald{\'e}s and Felipez Fern{\'a}ndez V{\'a}zquez and {\'A}ngel S{\'a}nchez-Recalde and Guillermo Galeote and Santiago Jim{\'e}nez-Valero and Manuel Almeida and E L{\'o}pez de sa and Luis Calvo and Ignacio Maga{\~n}a Plaza and Jos{\'e}-luis L{\'o}pez-Send{\'o}n and J L R Martin},
  journal={Circulation. Cardiovascular interventions},
  year={2013},
  volume={6 1},
  pages={21-8}
}
BACKGROUND Patients with coronary total occlusions are at especially high risk for restenosis and new revascularizations. Sirolimus-eluting stents dramatically improved the clinical outcome of this subset of patients in randomized trials, but other drug-eluting stents, mainly the everolimus-eluting stent (currently the most frequently used stent), have not yet been evaluated in patients with coronary total occlusions. The objective was to compare the second-generation everolimus-eluting stent… CONTINUE READING